1. Home
  2. EHAB vs ENGN Comparison

EHAB vs ENGN Comparison

Compare EHAB & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Enhabit Inc.

EHAB

Enhabit Inc.

HOLD

Current Price

$13.61

Market Cap

690.9M

Sector

Health Care

ML Signal

HOLD

Logo enGene Holdings Inc.

ENGN

enGene Holdings Inc.

HOLD

Current Price

$7.23

Market Cap

647.1M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
EHAB
ENGN
Founded
2014
1999
Country
United States
Canada
Employees
N/A
82
Industry
Hospital/Nursing Management
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
690.9M
647.1M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
EHAB
ENGN
Price
$13.61
$7.23
Analyst Decision
Hold
Buy
Analyst Count
5
5
Target Price
$13.84
$21.00
AVG Volume (30 Days)
2.5M
479.7K
Earning Date
06-08-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
97.11
N/A
EPS
N/A
N/A
Revenue
$1,060,000,000.00
N/A
Revenue This Year
$6.23
N/A
Revenue Next Year
$4.35
N/A
P/E Ratio
N/A
N/A
Revenue Growth
2.44
N/A
52 Week Low
$6.47
$2.66
52 Week High
$13.66
$12.25

Technical Indicators

Market Signals
Indicator
EHAB
ENGN
Relative Strength Index (RSI) 79.57 34.06
Support Level $10.79 $6.03
Resistance Level $13.65 $7.33
Average True Range (ATR) 0.03 0.63
MACD -0.07 -0.27
Stochastic Oscillator 55.00 16.98

Price Performance

Historical Comparison
EHAB
ENGN

About EHAB Enhabit Inc.

Enhabit Inc provides home health and hospice services in the United States. Its reportable segments are Home Health and Hospice. The Home Health segment includes a comprehensive range of Medicare-certified home nursing services for adult patients in need of care. These services include, among others, skilled nursing, physical, occupational, and speech therapy, medical social work, and home health aide services. The Hospice segment focuses on the quality of life for patients who are experiencing a life-limiting illness while treating the person and symptoms of the disease, rather than the disease itself. The company generates a majority of its revenue from the Home Health segment.

About ENGN enGene Holdings Inc.

enGene Holdings Inc is a clinical-stage biotechnology company mainstreaming genetic medicine through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs, beginning with non-muscle invasive bladder cancer (NMIBC). The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.

Share on Social Networks: